100.00% -0.1743

Handel nachbörslich: .07 0.07 +

Sangamo Therapeutics Inc (SGMO)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten

Sangamo Therapeutics Inc (SGMO)

Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten

Gene Therapy Co. Sangamo Gets Initial OK For $30M DIP - Law360

A Gene-Therapy Pioneer Just Filed For Chapter 11 Bankruptcy—Now Eli Lilly Wants Its Tech - inc.com

Biotech firm files for bankruptcy with $115M debt; Eli Lilly, Astellas bet on it anyway - MassLive

Case Summary: Sangamo Therapeutics Chapter 11 - Bondoro

Inside Sangamo Therapeutics' bankruptcy: Dwindling choices, millions of dollars, more layoffs - The Business Journals

Sangamo files for bankruptcy as Lilly and Astellas target assets - The Pharmaletter

Paul Weiss Advises Lilly on Sangamo Chapter 11 Bid - Lawyer Monthly

Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor - Yahoo Finance

Eli Lilly Enters Into Agreement to Acquire Sangamo Assets as Stalking Horse Bidder in Chapter 11 Auction - Paul, Weiss

Sangamo Therapeutics | 8-K/A: Current report (Amendment) - Moomoo

Sangamo Therapeutics | 8-K: Current report - Moomoo

Form 8K Sangamo Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa

Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle - Benzinga

UPDATE: Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy - BioSpace

Eli Lilly And Company entered into asset sale agreement to acquire Certain Assets from Sangamo Therapeutics, Inc.. - marketscreener.com

Sangamo files for Chapter 11, signs asset sale deals with Lilly - Investing.com UK

A Gene Therapy Biotech Firm Has Filed for Chapter 11 Bankruptcy - WhatNow

Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans - Law360

Sangamo Therapeutics Initiates Chapter 11 and Asset Sales - TipRanks

Sangamo Therapeutics files for bankruptcy after unique 30-year run - The Business Journals

Sangamo Therapeutics files for Chapter 11 bankruptcy - MSN

Sangamo Therapeutics Sets Stalking Horse Sales: $50M to Eli Lilly, Up to $50M to Astellas - TradingView

Sangamo Therapeutics Files for Chapter 11 Bankruptcy Protection - citybiz

Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas - The Manila Times

Sangamo Therapeutics (SGMO) Files for Chapter 11 Bankruptcy Prot - GuruFocus

Sangamo falls after Chapter 11 bankruptcy filing; Eli Lilly and Astellas to acquire key assets - Seeking Alpha

Sangamo Therapeutics, Inc. Filed for Bankruptcy - marketscreener.com

Sangamo Therapeutics(SGMO) Stock Options Chain | Quotes & News - Moomoo

Sangamo Therapeutics Inc (SGMO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Sangamo Therapeutics Inc (SGMO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Sangamo Therapeutics Inc (SGMO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Sangamo Therapeutics Inc (SGMO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Sangamo Therapeutics (SGMO) Hovers at $0.15: Biotech Micro-Cap Stuck in Tight Trading RangeQuality ETF - Město Břeclav

Deal Dispatch: Carlyle Buys Chung Ho Group, Second Nature Brands Acquires Tillamook Country Smoker, GoHealth Bankruptcy - Benzinga

Fabry Disease Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutic - Barchart.com

Sangamo Therapeutics explores strategic alternatives after burning through $1.6 billion - The Business Journals

Sangamo hires Raymond James to explore strategic alternatives By Investing.com - Investing.com Australia

Sangamo hires Raymond James to explore strategic alternatives - Investing.com

Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders - The Manila Times

Sangamo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Jain Nikunj - Moomoo

Sangamo (SGMO) executive shares withheld to cover RSU tax obligations - Stock Titan

Sangamo (SGMO) SVP surrenders 4,036 shares for RSU tax withholding - Stock Titan

Sangamo (SGMO) SVP uses 4,036 shares to cover RSU tax - Stock Titan

Sangamo Therapeutics (SGMO) CEO surrenders RSU shares to cover taxes - Stock Titan

Sangamo presents primate data for prion suppressor ST-506 - BioWorld News

Sangamo Therapeutics (SGMO) reports Q1 loss, misses revenue estimates - MSN

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2026 Earnings Call Transcript - Insider Monkey

Sangamo Therapeutics Reports No Unregistered Equity Sales or Share Repurchases for the Period - TipRanks

Sangamo Therapeutics, Inc. (SGMO) Presents at 29th ASGCT Annual Meeting 2026Slideshow - Seeking Alpha

Finance Watch: Sangamo Once Again Nearing The End Of Its Cash - Citeline News & Insights

Sangamo Therapeutics | SCHEDULE 13G: Others - Moomoo

Sangamo Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (OTCMKTS:SGMO) 2026-05-15 - Seeking Alpha

Q1 2026 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus

Sangamo Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results - The Manila Times

Sangamo Therapeutics (SGMO) Q1 2026 Earnings: EPS -$0.08 vs $0.0 - GuruFocus

Sangamo Therapeutics (SGMO) Advances BLA Submission Amid OTCQB T - GuruFocus

Ähnlich wie SGMO